Serina Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
AMEX
Farrell Simon, a Director of Serina Therapeutics, Inc., received 30,500 shares of common stock on July 22, 2026.
AMEX
Serina Therapeutics, Inc. reports a stock purchase by Director Stephen K. Brannan.
AMEX
Director Karen J. Wilson of Serina Therapeutics, Inc. has reported the acquisition of common stock through multiple transactions.
AMEX
Serina Therapeutics CEO Steven A. Ledger has acquired 10,100 shares of common stock in a series of transactions.
AMEX
Serina Therapeutics, Inc. reports that SVP Srini Tenjarla acquired stock options for 85,558 shares.
AMEX
Steven A. Ledger, CEO of Serina Therapeutics, Inc., acquired stock options for 380,825 shares, with vesting scheduled over four years.
AMEX
Serina Therapeutics, Inc. reports that Chief Financial Officer Gregory S. Curhan acquired stock options on May 21, 2026.
AMEX
Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc., acquired stock options for 85,558 shares on May 21, 2026.
AMEX
Director Karen J. Wilson of Serina Therapeutics, Inc. reported the acquisition of 20,000 shares of common stock through multiple transactions on May 21st and May 22nd, 2026.
AMEX
Director Richard Peter Marshall acquired 12,183 shares of Serina Therapeutics, Inc. common stock at a weighted average price of $1.65.
AMEX
Director Gregory Bailey acquired 59,667 shares of Serina Therapeutics common stock on March 31, 2026, for $1.94 per share, increasing his beneficial ownership.
AMEX
Serina Therapeutics, Inc. reports a transaction where Director Venkatesan Jay acquired 7,553 shares of common stock.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold the acquired common stock under a Rule 10b5-1 plan.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and immediately sold the acquired common stock under a Rule 10b5-1 plan.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, was granted 69,000 stock options with an exercise price of $2.76.
AMEX
Serina Therapeutics' SVP, CMC & Formulation, Srini Tenjarla, was granted 69,000 stock options with an exercise price of $2.76, vesting over four years.
AMEX
Serina Therapeutics Director Simba Gill acquired 92,000 stock options with an exercise price of $2.76, vesting over four years.
AMEX
Serina Therapeutics' CEO, Steven A. Ledger, was granted 230,100 stock options with a $2.76 exercise price, vesting over four years.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and immediately sold 6,500 shares of common stock.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised options and immediately sold 6,500 shares of common stock.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 2,500 shares of common stock under a Rule 10b5-1 plan.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, executed pre-planned sales of common stock totaling 4,000 shares over two days in January 2026.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, sold 6,500 shares of common stock after exercising options, pursuant to a pre-arranged 10b5-1 trading plan.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 13,000 shares of common stock.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and immediately sold 4,100 shares of common stock for a profit.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 5,673 shares of common stock.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 3,227 shares of common stock under a pre-arranged 10b5-1 plan.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and immediately sold the resulting common stock shares.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, sold 3,555 shares of common stock after exercising options, as disclosed in a Form 4 filing.
AMEX
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, sold common stock after exercising stock options in two separate, pre-planned transactions.